大麻素受体激动剂WIN55对成骨分化及大鼠脊柱融合的影响
该临床前研究评估大麻素受体激动剂WIN55,212-2(WIN55)对大鼠骨髓基质细胞成骨分化的体外影响,以及在45只雌性Sprague Dawley大鼠L4-L5后外侧脊柱融合模型中的骨再生与融合效果。结果显示WIN55未抑制成骨分化、骨基质矿化或脊柱融合,支持其作为术后镇痛替代方案的进一步研究。
要点
- WIN55不抑制大鼠骨髓基质细胞的Runx2、Alpl表达、ALP活性及矿化。
- 在大鼠脊柱融合模型中,WIN55未显著影响融合评分、融合率或新生骨体积。
- 大麻素受体激动剂可作为骨科术后镇痛替代靶点进一步研究。
核心结论
- WIN55对大鼠成骨分化、骨再生及脊柱融合无不良影响。
研究设计与样本
- 体外用大鼠骨髓基质细胞在标准或成骨培养基中暴露于溶剂或WIN55,检测Runx2、Alpl、ALP活性及矿化。
- 体内用45只雌性Sprague Dawley大鼠(每组n=15)行L4-L5后外侧脊柱融合,双侧植入预载低剂量rhBMP-2(0.5 μg/植入物)的胶原支架。
- 术后每日腹腔注射溶剂或0.5或2.5 mg/kg WIN55,持续5天。
主要发现
- 溶剂组与WIN55组细胞的Runx2和Alpl mRNA表达水平相似。
- WIN55未抑制ALP活性或骨基质矿化。
- 各组间平均融合评分、融合率及新生骨体积无显著差异。
临床怎么用
- 提示大麻素受体激动剂可作为脊柱融合等骨科术后镇痛的潜在替代方案进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: After spinal surgery and other orthopaedic procedures, most patients receive opioids for pain, leading to potential complications such as pseudarthrosis and opioid abuse associated with long-term use. As an alternative, the endocannabinoid system has been shown to have antinociceptive activity, while contributing to bone homeostasis via the CB1 and CB2 cannabinoid receptors. This study evaluates the impact of the cannabinoid receptor agonist WIN55,212-2 (WIN55) on osteogenic differentiation in vitro as well as bone regeneration and spinal fusion in a preclinical rat model. METHODS: Primary rat bone marrow stromal cells were cultured in standard or osteogenic media and exposed to vehicle alone or WIN55. Runx2 and Alkaline phosphatase (Alpl) were quantified via qPCR (quantitative real-time polymerase chain reaction), followed by assessment of ALP activity and matrix mineralization. For in vivo evaluation, 45 female Sprague Dawley rats (n = 15 per group) underwent L4-L5 posterolateral spinal fusion with bilateral placement of collagen scaffolds preloaded with low-dose rhBMP-2 (recombinant human bone morphogenetic protein-2; 0.5 μg/implant). Postoperatively, rats received the vehicle alone or 0.5 or 2.5 mg/kg WIN55 via daily intraperitoneal injections for 5 days. Bone regeneration and spinal fusion were assessed using radiography, manual palpation-based fusion scoring, microcomputed tomography imaging, and histology. RESULTS: mRNA expression levels of Runx2 and Alp were similar among cells treated with vehicle alone and WIN55. Likewise, exposure to WIN55 did not inhibit ALP activity or bone matrix mineralization. In this animal model, no significant differences were found among groups with regard to mean fusion score, fusion rate, or new bone volume. CONCLUSIONS: WIN55 showed no adverse impact on osteogenic differentiation, bone regeneration, and spinal fusion. This supports that cannabinoid receptor agonists should be further investigated as a potential alternative approach for postoperative analgesia following spinal fusion and other orthopaedic procedures requiring bone-healing. CLINICAL RELEVANCE: The identification of alternative treatments for postoperative pain following orthopaedic surgical procedures is crucial in combating the ongoing opioid abuse crisis. The endocannabinoid system may represent a viable alternative target for addressing orthopaedic postoperative pain.
引用
- Yun C, Haleem MS, Jeong S, et al. Effect of Postoperative Analgesic Exposure to the Cannabinoid Receptor Agonist WIN55 on Osteogenic Differentiation and Spinal Fusion in Rats. J Bone Joint Surg Am. 2021. PMID: 33759484. doi:10.2106/JBJS.20.00573
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。